Phase 3 N=601 Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
Dry Eye Syndrome
Primary: Ocular Discomfort — 0.07; -0.04 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma · Refractory Mantle Cell Lymphoma
Primary: Percent of Participants With Best Overall Objective Response or Complete Response/Partial Response (CR/PR) — 89 percentage of participants
N/A N=756 Views on COVID-19 and Vaccination
Covid19
Primary: Number of Participants Who Became Less Hesitant About the COVID-19 Vaccine After Receiving a Physician Message — 23; 26; 43; 35 Participants
Phase 2 N=27 A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
Primary Myelofibrosis · Polycythemia Vera · Post-Essential Thrombocythemia Myelofibrosis
Primary: Stage 1 Main Phase: Overall Response Rate (ORR) — 37.5; 14.3; 33.3; 50.0 Percentage of Participants
Phase 3 N=2,127 MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States
Healthy
Primary: Number of Participants With Respiratory Syncytial Virus (RSV) Hospitalization — 80; 21 Participants — p=<0.001
Phase 2 N=8 Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis
Acute Pancreatitis
Primary: Change in Peak Bicarbonate Concentration, Measured Using Endoscopic Pancreatic Function Test (ePFT) — -8.20; 5.50 mmol/l
N/A N=254 A Unified Intervention for Young Gay and Bisexual Men's Minority Stress, Mental Health, and HIV Risk
HIV · Acquired Immunodeficiency Syndrome
Primary: Any Condomless Anal Sex Acts — 43; 47; 17; 38 Participants — p=0.52
Phase 3 N=458 Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Lymphoma,Non-Hodgkin
Primary: Progression Free Survival (PFS) Based on Independent Central Review. — 21.5; 13.8; 23.2; 13.8 Months — p=0.000002
Phase 2 N=199 The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking
Cannabis Intoxication
Primary: Change in Composite Drive Score (CDS) From Pre-smoking Simulation — -.09; .12; .01; -.17 z-score — p=<0.001
N/A N=40 Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic
Gastrointestinal Disease · Infectious Disease · Capsule Endoscopy
Primary: Number of Participants With Complete Observation — 20; 20 Participants
Phase 3 N=162 A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
Growth Hormone Deficiency, Pediatric · hGH (Human Growth Hormone) · Endocrine System Diseases
Primary: Annualized Height Velocity at 52 Weeks for Weekly Lonapegsomatropin and Daily hGH Treatment Groups — 11.17; 10.31 cm/year — p=0.0088
N/A N=521 Testing the Effectiveness of a Falls Prevention System
High Risk for Falling
Primary: High Risk Fall Rate — 0 falls/1000 patient days
N/A N=125 Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
Chronic Myelomonocytic Leukemia · Chronic Myeloid Leukemia · Polycythemia Vera
Primary: Number of Participants With a Complete Response (CR) — 0; 0; 2; 0 participants
N/A N=278 Clinical Follow-up of Anti-Carbamylated Antibody Status in Rheumatoid Arthritis
RheumatoId Arthritis
Primary: DAS28-ESR — 3.75; 3.72; 3.59; 3.69 units on a scale — p=0.82
Phase 3 N=146 A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
Growth Hormone Deficiency, Pediatric · Endocrine System Diseases · Hormone Deficiency
Primary: Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] — 83; 6; 1; 0 Participants